The Indiana Biosciences Research Institute has named Dr. Alan Palkowitz president and chief executive officer. The IBRI says the research scientist will continue his work at the Indiana University School of Medicine as a professor of medicine.
Palkowitz directs the IUSM-Purdue TaRget Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) Center.
IBRI said Palkowitz also leads the IU Precision Health Initiative’s chemical biology and biotherapeutics scientific pillar.
“Having spent time in industry and academia, Alan understands the many opportunities for collaboration to improve the lives of Hoosiers,” said Daniel Evans, Jr., chairman of the IBRI board of directors. “He shares our passion for translational research and our vision to build a world-class organization that catalyzes activities across the life sciences ecosystem.”
Before joining IUSM, Palkowitz served as the vice president of Discovery Chemistry Research and Technologies at Indianapolis-based Eli Lilly and Co. (NYSE: LLY), where he worked for 28 years.
Palkowitz joins the staff at a time when IBRI is moving into its new headquarters at 16 Tech Innovation Building 1.
The institute expects the move, which begins next week, will open the door for more collaboration in life sciences.
“The IBRI has an opportunity to emerge as a key strategic partner with industry and regional academic centers to find innovative solutions to some of the most challenging biomedical problems,” said Palkowitz. “Working together, I believe we can achieve great results to advance science, benefit patients and grow our entrepreneurial biomedical community.”
In the video below, Business of Health reporter Kylie Veleta talks with IBRI Facilities and Lab Operations Manager Natalie Stull about the move to 16 Tech.